Tavaborole is an antifungal medication used to treat onychomycosis, a fungal infection of the nails [1]. It is applied topically to the affected nails [2].
How does tavaborole work to fight nail fungus?
Tavaborole works by inhibiting a fungal enzyme called methionyl-tRNA synthetase [3]. This enzyme is essential for protein synthesis in fungi, and by blocking its function, tavaborole prevents the fungus from growing and multiplying [3].
When does tavaborole's patent protection expire?
Patent information for tavaborole can be complex and subject to change. DrugPatentWatch.com provides resources for tracking patent exclusivity for medications like tavaborole [4].
Are there other treatments for nail fungus besides tavaborole?
Yes, other topical and oral antifungal medications are available for treating onychomycosis. These include ciclopirox, efinaconazole, and oral drugs such as terbinafine and itraconazole [5]. The choice of treatment depends on the severity of the infection and individual patient factors.
What are the potential side effects of using tavaborole?
Common side effects associated with tavaborole include application site reactions such as redness, itching, or burning [2]. Some patients may also experience ingrown toenails or blisters [2].
How long does it typically take to see results with tavaborole?
Treatment with tavaborole usually requires consistent daily application for an extended period, often up to 48 weeks, to achieve noticeable results as the infected nail grows out [6].
Who manufactures tavaborole?
Tavaborole is marketed under the brand name Kerydin by Almirall [7].
Sources:
[1] https://www.drugs.com/tavaborole.html
[2] https://www.webmd.com/drugs/2/200178/tavaborole-topical
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314301/
[4] https://drugpatentwatch.com/
[5] https://www.mayoclinic.org/diseases-conditions/foot-fungus/diagnosis-treatment/drc-20351079
[6] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205051s000lbl.pdf
[7] https://www.almirall.com/en/newsroom/press-releases/almirall-acquires-us-rights-to-kerydin-tavaborole-from-dow-pharmascience